Download PDF
Semin Thromb Hemost 2010; 36(2): 185-194
DOI: 10.1055/s-0030-1251503
© Thieme Medical Publishers

The Role of HMGB1/RAGE in Inflammatory Cardiomyopathy

Hans C. Volz1 , Ziya Kaya1 , Hugo A. Katus1 , Martin Andrassy1
  • 1Department of Medicine III, University of Heidelberg, Heidelberg, Germany
Further Information

Publication History

Publication Date:
22 April 2010 (online)

    Permissions and Reprints

ABSTRACT

Heart failure is an increasingly prevalent disorder with considerable morbidity and mortality. Although many causal mechanisms such as inherited cardiomyopathies, ischemic cardiomyopathy, or muscular overload are easily identified in clinical practice, the events that determine the progression of cardiac injury to heart failure and adverse ventricular remodeling are still unclear. Yet there is compelling evidence that inflammatory mechanisms contribute to the progression of heart failure. High-mobility group box-1 (HMGB1) is a newly recognized potent innate “danger signal” that is released by necrotic cells and by activated immune cells. HMGB1 signals via the receptor for advanced glycation end-product (RAGE) and members of the toll-like receptor (TLR) family. We have demonstrated an important role for HMGB1 and RAGE in the pathogenesis of early- and late-phase complications following ischemia/reperfusion (I/R) injury of the heart. In addition, enhanced postmyocardial infarction remodeling in type 1 diabetes mellitus was partially mediated by HMGB1 activation. We propose that the interaction of HMGB1 and RAGE is a key component initiating and sustaining the inflammatory response in inflammatory cardiomyopathy eventually leading to heart failure. Thus HMGB1-antagonizing gene therapy represents a new therapeutic strategy.

KEYWORDS

HMGB1 - inflammation - innate immunity - inflammatory cardiomyopathy

REFERENCES

  • 1 Alla F, Zannad F, Filippatos G. Epidemiology of acute heart failure syndromes.  Heart Fail Rev. 2007;  12(2) 91-95
    CrossrefPubMedGoogle Scholar
  • 2 Schocken D D, Benjamin E J, Fonarow G C American Heart Association Council on Epidemiology and Prevention et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group.  Circulation. 2008;  117(19) 2544-2565
    CrossrefPubMedGoogle Scholar
  • 3 Rauchhaus M, Doehner W, Francis D P et al.. Plasma cytokine parameters and mortality in patients with chronic heart failure.  Circulation. 2000;  102(25) 3060-3067
    PubMedGoogle Scholar
  • 4 Deswal A, Petersen N J, Feldman A M, Young J B, White B G, Mann D L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).  Circulation. 2001;  103(16) 2055-2059
    CrossrefPubMedGoogle Scholar
  • 5 Kandolf R. Myocarditis and cardiomyopathy [in German].  Verh Dtsch Ges Pathol. 1996;  80 127-138
    PubMedGoogle Scholar
  • 6 Pisani B, Taylor D O, Mason J W. Inflammatory myocardial diseases and cardiomyopathies.  Am J Med. 1997;  102(5) 459-469
    CrossrefPubMedGoogle Scholar
  • 7 Feldman A M, McNamara D. Myocarditis.  N Engl J Med. 2000;  343(19) 1388-1398
    CrossrefPubMedGoogle Scholar
  • 8 Kindermann I, Kindermann M, Kandolf R et al.. Predictors of outcome in patients with suspected myocarditis.  Circulation. 2008;  118(6) 639-648
    CrossrefPubMedGoogle Scholar
  • 9 D'Ambrosio A, Patti G, Manzoli A et al.. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review.  Heart. 2001;  85(5) 499-504
    CrossrefPubMedGoogle Scholar
  • 10 Richardson P, McKenna W, Bristow M et al.. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.  Circulation. 1996;  93(5) 841-842
    PubMedGoogle Scholar
  • 11 Codd M B, Sugrue D D, Gersh B J, Melton III L J. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984.  Circulation. 1989;  80(3) 564-572
    PubMedGoogle Scholar
  • 12 Cowie M R, Mosterd A, Wood D A et al.. The epidemiology of heart failure.  Eur Heart J. 1997;  18(2) 208-225
    PubMedGoogle Scholar
  • 13 Smith S C, Allen P M. Myosin-induced acute myocarditis is a T cell-mediated disease.  J Immunol. 1991;  147(7) 2141-2147
    PubMedGoogle Scholar
  • 14 Liao L, Sindhwani R, Rojkind M, Factor S, Leinwand L, Diamond B. Antibody-mediated autoimmune myocarditis depends on genetically determined target organ sensitivity.  J Exp Med. 1995;  181(3) 1123-1131
    CrossrefPubMedGoogle Scholar
  • 15 Huber S A, Lodge P A. Coxsackievirus B-3 myocarditis. Identification of different pathogenic mechanisms in DBA/2 and Balb/c mice.  Am J Pathol. 1986;  122(2) 284-291
    PubMedGoogle Scholar
  • 16 Kaya Z, Afanasyeva M, Wang Y et al.. Contribution of the innate immune system to autoimmune myocarditis: a role for complement.  Nat Immunol. 2001;  2(8) 739-745
    CrossrefPubMedGoogle Scholar
  • 17 Park J S, Arcaroli J, Yum H K et al.. Activation of gene expression in human neutrophils by high mobility group box 1 protein.  Am J Physiol Cell Physiol. 2003;  284(4) C870-C879
    PubMedGoogle Scholar
  • 18 Scaffidi P, Misteli T, Bianchi M E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.  Nature. 2002;  418(6894) 191-195
    CrossrefPubMedGoogle Scholar
  • 19 Wang H, Bloom O, Zhang M et al.. HMG-1 as a late mediator of endotoxin lethality in mice.  Science. 1999;  285(5425) 248-251
    CrossrefPubMedGoogle Scholar
  • 20 Andersson U, Wang H, Palmblad K et al.. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes.  J Exp Med. 2000;  192(4) 565-570
    CrossrefPubMedGoogle Scholar
  • 21 Treutiger C J, Mullins G E, Johansson A S et al.. High mobility group 1 B-box mediates activation of human endothelium.  J Intern Med. 2003;  254(4) 375-385
    CrossrefPubMedGoogle Scholar
  • 22 Rovere-Querini P, Capobianco A, Scaffidi P et al.. HMGB1 is an endogenous immune adjuvant released by necrotic cells.  EMBO Rep. 2004;  5(8) 825-830
    CrossrefPubMedGoogle Scholar
  • 23 Yang H, Ochani M, Li J et al.. Reversing established sepsis with antagonists of endogenous high-mobility group box 1.  Proc Natl Acad Sci U S A. 2004;  101(1) 296-301
    CrossrefPubMedGoogle Scholar
  • 24 Andrassy M, Volz H C, Igwe J C et al.. High-mobility group box-1 in ischemia-reperfusion injury of the heart.  Circulation. 2008;  117(25) 3216-3226
    CrossrefPubMedGoogle Scholar
  • 25 Kokkola R, Sundberg E, Ulfgren A K et al.. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis.  Arthritis Rheum. 2002;  46(10) 2598-2603
    CrossrefPubMedGoogle Scholar
  • 26 Ulfgren A K, Grundtman C, Borg K et al.. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids.  Arthritis Rheum. 2004;  50(5) 1586-1594
    CrossrefPubMedGoogle Scholar
  • 27 Park L, Raman K G, Lee K J et al.. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.  Nat Med. 1998;  4(9) 1025-1031
    CrossrefPubMedGoogle Scholar
  • 28 Bierhaus A, Haslbeck K M, Humpert P M et al.. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily.  J Clin Invest. 2004;  114(12) 1741-1751
    CrossrefPubMedGoogle Scholar
  • 29 Haslbeck K M, Bierhaus A, Erwin S et al.. Receptor for advanced glycation endproduct (RAGE)-mediated nuclear factor-kappaB activation in vasculitic neuropathy.  Muscle Nerve. 2004;  29(6) 853-860
    CrossrefPubMedGoogle Scholar
  • 30 Haslbeck K M, Friess U, Schleicher E D et al.. The RAGE pathway in inflammatory myopathies and limb girdle muscular dystrophy.  Acta Neuropathol. 2005;  110(3) 247-254
    CrossrefPubMedGoogle Scholar
  • 31 Sakaguchi T, Yan S F, Yan S D et al.. Central role of RAGE-dependent neointimal expansion in arterial restenosis.  J Clin Invest. 2003;  111(7) 959-972
    CrossrefPubMedGoogle Scholar
  • 32 Andrassy M, Igwe J, Autschbach F et al.. Posttranslationally modified proteins as mediators of sustained intestinal inflammation.  Am J Pathol. 2006;  169(4) 1223-1237
    CrossrefPubMedGoogle Scholar
  • 33 Yan S F, Ramasamy R, Naka Y, Schmidt A M. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond.  Circ Res. 2003;  93(12) 1159-1169
    CrossrefPubMedGoogle Scholar
  • 34 Hori O, Brett J, Slattery T et al.. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system.  J Biol Chem. 1995;  270(43) 25752-25761
    CrossrefPubMedGoogle Scholar
  • 35 Kokkola R, Andersson A, Mullins G et al.. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages.  Scand J Immunol. 2005;  61(1) 1-9
    CrossrefPubMedGoogle Scholar
  • 36 Yang D, Chen Q, Yang H, Tracey K J, Bustin M, Oppenheim J J. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin.  J Leukoc Biol. 2007;  81(1) 59-66
    CrossrefPubMedGoogle Scholar
  • 37 Dumitriu I E, Baruah P, Valentinis B et al.. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products.  J Immunol. 2005;  174(12) 7506-7515
    PubMedGoogle Scholar
  • 38 Jaulmes A, Thierry S, Janvier B, Raymondjean M, Maréchal V. Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1beta.  FASEB J. 2006;  20(10) 1727-1729
    CrossrefPubMedGoogle Scholar
  • 39 Fiuza C, Bustin M, Talwar S et al.. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells.  Blood. 2003;  101(7) 2652-2660
    CrossrefPubMedGoogle Scholar
  • 40 Mitola S, Belleri M, Urbinati C et al.. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine.  J Immunol. 2006;  176(1) 12-15
    PubMedGoogle Scholar
  • 41 Huttunen H J, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways.  J Biol Chem. 1999;  274(28) 19919-19924
    CrossrefPubMedGoogle Scholar
  • 42 Bierhaus A, Schiekofer S, Schwaninger M et al.. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB.  Diabetes. 2001;  50(12) 2792-2808
    CrossrefPubMedGoogle Scholar
  • 43 Li J, Schmidt A M. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products.  J Biol Chem. 1997;  272(26) 16498-16506
    CrossrefPubMedGoogle Scholar
  • 44 Harja E, Bu D X, Hudson B I et al.. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice.  J Clin Invest. 2008;  118(1) 183-194
    CrossrefPubMedGoogle Scholar
  • 45 Göser S, Andrassy M, Buss S J et al.. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium.  Circulation. 2006;  114(16) 1693-1702
    CrossrefPubMedGoogle Scholar
  • 46 Liang Y, Zhou Y, Shen P. NF-kappaB and its regulation on the immune system.  Cell Mol Immunol. 2004;  1(5) 343-350
    PubMedGoogle Scholar

Martin AndrassyM.D. 

Department of Medicine III, University of Heidelberg

INF 410, 69120 Heidelberg, Germany

Email: martin.andrassy@med.uni-heidelberg.de